Board of Directors

Richard F. Pops, Chairman and Chief Executive Officer

Richard Pops serves as Chairman and Chief Executive Officer of Alkermes. He joined Alkermes as CEO in 1991. Under his leadership, Alkermes has grown from a privately held company with 25 employees to an international, publicly traded biopharmaceutical company with more than 2,000 employees. Alkermes has a diversified commercial product portfolio and a R&D pipeline focused on neuroscience and oncology. Mr. Pops currently serves on the board of Directors of Neurocrine Biosciences, Inc., the Biotechnology Industry Organization (BIO) and the Pharmaceutical Research and Manufacturers of America (PhRMA).

David W. Anstice

Mr. Anstice served as Executive Vice President of Merck & Co., Inc. from 2006 to 2008 with responsibility for enterprise strategy and implementation. During separate parts of this period he served as acting President, Global Human Health and as President of Merck’s business in Japan. From 2003 to 2006, Mr. Anstice served as President of Merck, with responsibility for Merck’s Asia Pacific businesses. In his 34 years with Merck, he held a variety of positions with their worldwide ventures, including President, U.S. Human Health; President, U.S./Canada; President, Human Health, the Americas; and President, Human Health, Europe. Mr. Anstice holds a Bachelor of Economics from the University of Sydney. Mr. Anstice is an Adjunct Professor at the University of Sydney Business School and serves as a member of the board of the University of Sydney USA Foundation. Mr. Anstice is also a non-executive director of NeuClone Pharmaceuticals Pty. Ltd.

Robert A. Breyer

Mr. Breyer served as the President of Alkermes from July 1994 until his retirement in December 2001 and Chief Operating Officer from July 1994 to February 2001. From August 1991 to December 1993, Mr. Breyer was President and General Manager of Eli Lilly Italy, a subsidiary of Eli Lilly and Company. From September 1987 to August 1991, he was Senior Vice President, Marketing and Sales of IVAC Corporation, a subsidiary of Eli Lilly and Company. Mr. Breyer also previously served on the board of Directors of Lentigen, Inc.

Shane M. Cooke

Mr. Cooke served as President of Alkermes from September 2011 until his retirement in March 2018. He became a director of Alkermes upon his retirement. Mr. Cooke is Chairman of the Board of Alkermes Pharma Ireland Limited (“APIL”), a wholly-owned subsidiary of Alkermes, and has had that position since September 2011. From May 2007 to September 2011, Mr. Cooke was Executive Vice President of Elan Corporation, plc (“Elan”) and Head of Elan Drug Technologies. Mr. Cooke served as the Chief Financial Officer of Elan from July 2001, when he joined Elan, until May 2011. From May 2005 to September 2011, Mr. Cooke served as a director of Elan. Prior to joining Elan, Mr. Cooke was Chief Executive of Pembroke Capital Limited, an aviation leasing company, and prior to that, held a number of senior positions in finance in the banking and aviation industries. He is a chartered accountant. He is currently on the board of directors of Prothena Corporation plc, Endo International plc and UDG Healthcare plc, each a publicly traded company.

David A. Daglio

Mr. Daglio most recently served as a non-executive director of Mellon Investments Corporation (“Mellon”) from 2019 to January 2020 and as Executive Vice President, Chief Investment Officer and Executive Director of Mellon from 2017 to 2019. He also served as Mellon’s head of Opportunistic Value Strategies. Mr. Daglio joined Mellon in 1998 and over the subsequent two decades helped to design, launch, and manage a unique equity investing approach and architect and manage the merger of three unique companies to create the 12th largest U.S. Asset Manager. In these roles, Mr. Daglio worked with institutional clients and boards around the world, managed numerous investors and grew portfolio assets by more than five-fold. Mr. Daglio previously served as a director of The Boston Company and Mellon and currently serves as a director of Total Brain Ltd., an Australian publicly-traded company. He also recently served as Executive in Residence at the Rensselaer Lally School of Business. Prior to his investing career, Mr. Daglio was a management consultant at Deloitte and an engineer for The Dannon Company.

Wendy L. Dixon, Ph.D.

Dr. Dixon has extensive experience in the pharmaceutical and biotechnology industries, combining a technical background with experience in drug development, regulatory affairs and marketing. She directed the launch of and growth of more than 20 pharmaceutical products. From 2001 to 2009 she was Chief Marketing Officer and President, Global Marketing for Bristol-Myers Squibb where she served on the Executive Committee. From 1996 to 2001 she was Senior Vice President, Marketing at Merck & Co. and prior to that she held executive management positions at West Pharmaceuticals, Osteotech, and Centocor and various positions at SmithKline and French (now GlaxoSmithKline) in marketing, regulatory affairs, project management and as a biochemist. Dr. Dixon is on the boards of directors of Incyte Corporation, Voyager Therapeutics, Inc., bluebird bio, Inc. and Arvinas, Inc. and was formerly on the boards of directors of Dentsply International, Orexigen Therapeutics, Sesen Bio, Inc. (formerly Eleven Biotherapeutics, Inc.) and Ardea Biosciences, Inc. She was a Senior Advisor to The Monitor Group, now Deloitte, from 2010 to 2012.

Richard B. Gaynor, M.D.

Dr. Gaynor serves as President, Chief of Research and Development at BioNTech US (previously Neon Therapeutics, Inc.), a leading company in the field of neoantigen-targeted cancer therapies. From November 2016 until May 2020, he was President of Research and Development at Neon Therapeutics. Prior to joining Neon, Dr. Gaynor held clinical development and medical affairs roles at Eli Lilly and Company from August 2002 to October 2016, including serving as Senior Vice President, Clinical Development and Medical Affairs of Lilly Oncology. During his time at Lilly, Dr. Gaynor chaired the Lilly Oncology Research and Development Committee and helped oversee various collaborations, including with General Electric, AstraZeneca, Merck and Bristol-Myers Squibb. Dr. Gaynor started his career in academia, initially serving on the faculty at UCLA School of Medicine for nine years, followed by eleven years at the University of Texas Southwestern Medical School, during which he spent time as the Chief of Hematology-Oncology and Director of the Simmons Cancer Center. Dr. Gaynor holds an M.D. from the University of Texas Southwestern Medical School and completed fellowship training in hematology-oncology at the UCLA School of Medicine. Dr. Gaynor is on the editorial boards of several scientific journals and has an extensive publication record totaling more than 140 scientific articles. He also serves on the boards of directors of Infinity Pharmaceuticals, Inc., a public biopharmaceutical company, and the Damon Runyon Cancer Research Foundation and sits on several committees for the American Association of Cancer Research and other leading cancer organizations.

Brian P. McKeon

Mr. McKeon serves as the Executive Vice President, Chief Financial Officer, and Treasurer of IDEXX Laboratories, Inc. (“IDEXX”), a public multinational corporation. He leads IDEXX’s finance, corporate development and strategy, and investor relations functions and, since June 2019, has overseen IDEXX’s livestock, water and human diagnostics businesses. Mr. McKeon served on the board of directors of IDEXX from 2003 to 2013, including serving as Chair of its Audit Committee and as a member of its Compensation Committee. Prior to joining IDEXX, Mr. McKeon served as Executive Vice President and Chief Financial Officer of Iron Mountain Incorporated from 2007 to 2013 and as Executive Vice President and Chief Financial Officer at the Timberland Company from 2000 to 2007. Prior to these roles, he held several finance and strategic planning roles at PepsiCo Inc., serving most recently as Vice President, Finance, at Pepsi-Cola, North America. Mr. McKeon previously served as a director of athenahealth, Inc. from September 2017 to February 2019.

Paul J. Mitchell

Mr. Mitchell served as the Chief Financial Officer and Treasurer of Kenet, Inc. from 2002 until 2009. Prior to joining Kenet, Mr. Mitchell was the Chief Financial Officer and Treasurer of Kopin Corporation from April 1985 through September 1998. From September 1998 through June 2001, Mr. Mitchell served in a consulting role at Kopin as Director of Strategic Planning. Prior to joining Kopin, Mr. Mitchell worked for the international accounting firm of Touche Ross & Co. from 1975 to 1984. Mr. Mitchell is President of Mitchell Financial Group and a member of the boards of directors of several private companies. He is a director of the Marblehead Youth Basketball Association. Mr. Mitchell is a graduate of College of the Holy Cross (B.A. Economics) and Northeastern University (M.S. Accounting) and he was previously a Certified Public Accountant.

Nancy L. Snyderman, M.D.

Dr. Snyderman most recently served as Chief Medical Editor at NBC News and has more than three decades of experience as a leading voice in healthcare and medicine. Dr. Snyderman is a board-certified Otolaryngologist-Head and Neck Surgeon and Fellow in the American College of Surgeons. She currently serves as a board member of Axonics Modulation Technologies, Inc., a medical device company, and Lyra Therapeutics, Inc., a clinical-stage therapeutics company. She is a Consulting Professor in the School of Global Health at the Stanford University Center for Innovation in Global Health and a Consulting Professor of Medical Communication in the School of Public Health at the University of Nebraska Medical Center. Dr. Snyderman co-founded the Stanford University-NBC News Global Media Fellowship. In addition, Dr. Snyderman has over 25 years of experience as a medical journalist at NBC News and ABC News. She has received distinguished honors, including Emmy Awards, an Edward R. Murrow Award, a Columbia University DuPont Award and a Gracie Award, for her reporting. Prior to her work in journalism, Dr. Snyderman worked at Johnson & Johnson as Senior Vice President, Corporate Communications. Dr. Snyderman attended medical school at the University of Nebraska and completed residencies in Pediatrics and Otolaryngology-Head and Neck Surgery at the University of Pittsburgh.

Frank Anders (“Andy”) Wilson

Mr. Wilson most recently served as Chief Financial Officer and Senior Vice President of PerkinElmer, Inc., a life sciences diagnostics, discovery and analytical solutions company, from 2009 to mid-2018, with responsibility for oversight of the organization’s growth strategy. Prior to PerkinElmer, Mr. Wilson held key business development and finance roles for over 12 years at Danaher Corporation, a global science and technology conglomerate, including the position of Corporate Vice President of Investor Relations. Earlier in his career, Mr. Wilson worked at AlliedSignal, Inc., now Honeywell International Inc., where he served as Vice President of Finance and Chief Financial Officer for the Commercial Avionics Systems division. Prior to AlliedSignal, Mr. Wilson’s work included financial and controllership positions of increasing responsibility at PepsiCo, Inc., as well as roles at E.F. Hutton and Company and KPMG Peat Marwick. Since 2018, Mr. Wilson has served as a member of the board of directors of Cabot Corporation, a public global specialty chemicals and performance materials company. From 2015 to 2019, he was a member of the board of directors of Sparton Corporation, where he last served as Chairman of the board. Mr. Wilson is a Certified Public Accountant.

Nancy J. Wysenski

Ms. Wysenski served as the Executive Vice President and Chief Commercial Officer of Vertex Pharmaceuticals Inc. from December 2009 through June 2012. Under her leadership, the commercial organization grew from 40 to 400 employees and the company’s first two product launches occurred. Prior to joining Vertex, Ms. Wysenski held the position of Chief Operating Officer of Endo Pharmaceuticals plc, where she led sales, marketing, commercial operations, supply chain management, human resources and various business development initiatives. Prior to her role at Endo, Ms. Wysenski participated in the establishment of EMD Pharmaceuticals, Inc., where she held various leadership positions, including the role of President and Chief Executive Officer from 2001 to 2006 and Vice President of Commercial from 1999 to 2001. From 1984 to 1998, Ms. Wysenski held several sales-focused roles at major pharmaceutical companies, including Vice President of Field Sales for Astra Merck, Inc. Ms. Wysenski serves on the boards of directors of Provention Bio, Inc., and Cytokinetics, Inc. She was previously on the boards of directors of Dova Pharmaceuticals Inc., Reata Pharmaceuticals, Inc., Inovio Pharmaceuticals, Inc., and Tetraphase Pharmaceuticals, Inc. She is a founder of the Research Triangle Park Chapter of the Healthcare Businesswomen’s Association and served on the Nominating Committee and National Advisory Board of the Healthcare Businesswomen’s Association.